10115944Development of a novel microneedle based technology with integrated delivery confirmation to enhance self-administration reliability of needle-free vaccines.ClosedCollaborative R&DInnovate UKThe healthcare and vaccine delivery sectors, while essential, face significant challenges in ensuring global vaccine accessibility and minimising wastage. These challenges are compounded by the reliance on cold chain logistics and the necessity for skilled healthcare personnel for vaccine administration. In response, CipherX and Nemaura have embarked on a ground-breaking project to develop the Self-administered Microneedle-Assisted Responsive Tattoo (S.M.A.R.T) vaccine-patch. This initiative aims to transform the Micro-Array Patch Vaccine (MAPV) landscape by introducing an innovative, user-friendly solution that reduces vaccine wastage and circumvents the limitations of the cold chain. Conventional MAPVs, despite their potential to mitigate cold-chain and wastage issues, fall short in terms of end-user confidence and verifiable self-administration. The S.M.A.R.T vaccine patch addresses these shortcomings by integrating a temporary-tattoo that visually confirms successful vaccine delivery, enhancing user confidence and promoting wider acceptance. This project is poised to make significant strides in the MAPV market, which is projected to grow from £2.3 billion in 2024 to £3.3 billion by 2029, with a compound annual growth rate (CAGR) of 6.83%. The collaboration between CipherX (with its expertise in microneedle-tattoo technology, and Nemaura-Pharma (a UK leader in MAP development), represents a strategic alignment of complementary strengths. Together, they aim to deliver a needle-free vaccination solution that is not only more accessible and efficient but also eliminates the need for skilled healthcare personnel for vaccine administration. This is particularly crucial in low-and-middle-income-countries (LMICs) and remote areas where healthcare resources are limited. The S.M.A.R.T vaccine-patch feasibility project will assess the integration of a visual indicator(CipherX) into an advanced MAPV system (Nemaura-Pharma), and conclude with an MAPV application study to compare delivery confidence between current gold-standard MAPV devices and the S.M.A.R.T vaccine-patch. This initiative not only addresses key challenges in global health but also aligns with international efforts to improve vaccine distribution and accessibility. By enhancing the usability and acceptance of MAPV technology, CipherX and Nemaura-Pharma aim to make a pivotal contribution to public health and vaccine technology, setting new standards in vaccine delivery and patient care.